Mindset Pharma Halftime Report 2022

Patents, Partnerships, New Data. These are just some of the topics discussed by Mindset’s CEO James Lanthier as he delivers his Halftime report for 2022. James discusses how the first half of 2022 has been especially busy as IP development and global partnership development remained at the forefront of corporate activity. James also provides us with some thoughts on what we can expect from MSET in the second half of 2022. Don’t miss out!

About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin in addition to its own proprietary compounds. The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, for its short-duration compounds, Mindset Families 2 & 4.